162 related articles for article (PubMed ID: 28739253)
21. Forkhead box protein O1 (FoxO1) regulates hepatic serine protease inhibitor B1 (serpinB1) expression in a non-cell-autonomous fashion.
El Ouaamari A; O-Sullivan I; Shirakawa J; Basile G; Zhang W; Roger S; Thomou T; Xu S; Qiang G; Liew CW; Kulkarni RN; Unterman TG
J Biol Chem; 2019 Jan; 294(3):1059-1069. PubMed ID: 30459233
[TBL] [Abstract][Full Text] [Related]
22. Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin.
Dallinga-Thie GM; Groenendijk M; Blom RN; De Bruin TW; De Kant E
J Lipid Res; 2001 Sep; 42(9):1450-6. PubMed ID: 11518765
[TBL] [Abstract][Full Text] [Related]
23. Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3' to the gene in the promoter of the adjacent convergently transcribed apoC-III gene.
Walsh A; Azrolan N; Wang K; Marcigliano A; O'Connell A; Breslow JL
J Lipid Res; 1993 Apr; 34(4):617-23. PubMed ID: 8496667
[TBL] [Abstract][Full Text] [Related]
24. Human apolipoprotein C-III - a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins.
Yao Z
Cardiovasc Hematol Disord Drug Targets; 2012 Dec; 12(2):133-40. PubMed ID: 23030451
[TBL] [Abstract][Full Text] [Related]
25. Elevated expression of forkhead box protein O1 (FoxO1) in alcohol-induced intestinal barrier dysfunction.
Wang Y; Tong J; Zou D; Chang B; Wang B; Wang B
Acta Histochem; 2013 Jul; 115(6):557-63. PubMed ID: 23347700
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
Zheng C; Khoo C; Furtado J; Sacks FM
Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
[TBL] [Abstract][Full Text] [Related]
27. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
Sajan MP; Lee MC; Foufelle F; Sajan J; Cleland C; Farese RV
Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047
[TBL] [Abstract][Full Text] [Related]
28. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice.
Kamagate A; Qu S; Perdomo G; Su D; Kim DH; Slusher S; Meseck M; Dong HH
J Clin Invest; 2008 Jun; 118(6):2347-64. PubMed ID: 18497885
[TBL] [Abstract][Full Text] [Related]
29. Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.
Qu S; Altomonte J; Perdomo G; He J; Fan Y; Kamagate A; Meseck M; Dong HH
Endocrinology; 2006 Dec; 147(12):5641-52. PubMed ID: 16997836
[TBL] [Abstract][Full Text] [Related]
30. Gegen Qinlian Decoction Ameliorates Hepatic Insulin Resistance by Silent Information Regulator1 (SIRT1)-Dependent Deacetylation of Forkhead Box O1 (FOXO1).
Sui M; Chen G; Mao X; Wei X; Chen Y; Liu C; Fan Y
Med Sci Monit; 2019 Nov; 25():8544-8553. PubMed ID: 31719515
[TBL] [Abstract][Full Text] [Related]
31. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E.
de Silva HV; Lauer SJ; Wang J; Simonet WS; Weisgraber KH; Mahley RW; Taylor JM
J Biol Chem; 1994 Jan; 269(3):2324-35. PubMed ID: 8294490
[TBL] [Abstract][Full Text] [Related]
33. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen.
Qin W; Sundaram M; Wang Y; Zhou H; Zhong S; Chang CC; Manhas S; Yao EF; Parks RJ; McFie PJ; Stone SJ; Jiang ZG; Wang C; Figeys D; Jia W; Yao Z
J Biol Chem; 2011 Aug; 286(31):27769-80. PubMed ID: 21676879
[TBL] [Abstract][Full Text] [Related]
34. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia.
Haeusler RA; Han S; Accili D
J Biol Chem; 2010 Aug; 285(35):26861-26868. PubMed ID: 20573950
[TBL] [Abstract][Full Text] [Related]
35. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB; Averna M
Curr Atheroscler Rep; 2023 Mar; 25(3):67-76. PubMed ID: 36689070
[TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.
Aroner SA; Furtado JD; Sacks FM; Tsai MY; Mukamal KJ; McClelland RL; Jensen MK
Diabetologia; 2019 Jun; 62(6):981-992. PubMed ID: 30949716
[TBL] [Abstract][Full Text] [Related]
37. FoxO1 regulates TLR4/MyD88/MD2-NF-κB inflammatory signalling in mucosal barrier injury of inflammatory bowel disease.
Han C; Guo L; Sheng Y; Yang Y; Wang J; Gu Y; Li W; Zhou X; Jiao Q
J Cell Mol Med; 2020 Mar; 24(6):3712-3723. PubMed ID: 32057181
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity.
Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT
Int J Mol Med; 2016 Mar; 37(3):743-54. PubMed ID: 26847930
[TBL] [Abstract][Full Text] [Related]
39. Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering.
Ramms B; Patel S; Sun X; Pessentheiner AR; Ducasa GM; Mullick AE; Lee RG; Crooke RM; Tsimikas S; Witztum JL; Gordts PL
JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35653195
[TBL] [Abstract][Full Text] [Related]
40. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
